Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Johnson & Johnson (NYSE:JNJ)

112.26
Delayed Data
As of Dec 09
 +1.27 / +1.14%
Today’s Change
94.28
Today|||52-Week Range
126.07
+9.29%
Year-to-Date
3 Safe Stocks You Can Buy Right Now
Dec 10 / MotleyFool.com - Paid Partner Content
Forget Pfizer: Here Are 3 Better Dividend Stocks
Dec 02 / MotleyFool.com - Paid Partner Content
The 3 Fastest-Growing Drug Classes Over the Next 5 Years
Dec 10 / MotleyFool.com - Paid Partner Content
MedTech Sails Through Macro Woes: Stocks in Focus
Dec 02 / Zacks.com - Paid Partner Content
Should Big Pharma Be Worried About a Trump Trade War?
Dec 10 / MotleyFool.com - Paid Partner Content
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Ro...
Dec 02 / Zacks.com - Paid Partner Content
Better Buy: Johnson & Johnson vs. Pfizer Inc.
Dec 08 / MotleyFool.com - Paid Partner Content
3 Small-Cap Biotech Stocks That Could Double in 2017
Dec 02 / MotleyFool.com - Paid Partner Content
3 Stocks That Propelled the Dow to a Fresh All-Time High
Dec 08 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytr...
Dec 02 / Zacks.com - Paid Partner Content
Trump Presidency Could Offer New Challenges for Shaky Drug Sector
Dec 08 / TheStreet.com - Paid Partner Content
MedTech Industry Stock Outlook - December 2016
Dec 01 / Zacks.com - Paid Partner Content
Better Buy: Johnson & Johnson vs. Eli Lilly
Dec 07 / MotleyFool.com - Paid Partner Content
Here's the Best Dividend Stock in Big Pharma
Dec 01 / MotleyFool.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Johnson & Johnson, Wells Fargo, Wal-Mart, Kimberly...
Dec 07 / Zacks.com - Paid Partner Content
Achillion, J&J to Initiate Phase IIb Study on HCV Combo
Dec 01 / Zacks.com - Paid Partner Content
Actelion is a Perfect Fit for Sanofi but Probably too Expensive: Exane BNP
Dec 07 / TheStreet.com - Paid Partner Content
Pfizer's Herceptin Biosimilar Meets Primary Endpoint in Study
Dec 01 / Zacks.com - Paid Partner Content
4 Small-Cap Stocks Worth Buying in 2017
Dec 07 / MotleyFool.com - Paid Partner Content
If You're in Your 70s, Consider Buying These 2 Stocks
Dec 01 / MotleyFool.com - Paid Partner Content
Sanofi and Johnson & Johnson May Battle for the Right to Overpay for Actelion
Dec 07 / MotleyFool.com - Paid Partner Content
Is an Actelion Deal Good for Johnson & Johnson Shareholders?
Nov 30 / MotleyFool.com - Paid Partner Content
Top Research Reports for December 6, 2016
Dec 06 / Zacks.com - Paid Partner Content
Quest to cure Alzheimer's disease exhibits symptoms of failure
Nov 30 / FT.com - Paid Partner Content
3 Top Healthcare Stocks
Dec 06 / MotleyFool.com - Paid Partner Content
J&J (JNJ) Stands Tall in 2016: Reasons for Outperformance
Nov 30 / Zacks.com - Paid Partner Content
AbbVie (ABBV) Presents Impressive Imbruvica Data at ASH
Dec 06 / Zacks.com - Paid Partner Content
Johnson & Johnson Throws Caution to the Wind With a Large Bid for Actelion
Nov 30 / MotleyFool.com - Paid Partner Content
Lilly: Jardiance Label to Add Cardiovascular Indication
Dec 06 / Zacks.com - Paid Partner Content
Big Pharma healthcare R&D steps out into the open
Nov 29 / FT.com - Paid Partner Content
5 Things You Must Know Before the Market Opens Tuesday
Dec 06 / TheStreet.com - Paid Partner Content
Actelion weighs complicated deal to combine with part of J&J
Nov 28 / FT.com - Paid Partner Content
Actelion Surges on Report of Sanofi Challenge to J&J Takeover Bid
Dec 06 / TheStreet.com - Paid Partner Content
Actelion: independent thinking
Nov 28 / FT.com - Paid Partner Content
European Stocks Slip Lower, Italy Gains in Mixed Start to Trading
Dec 06 / TheStreet.com - Paid Partner Content
Stock Market News for November 28, 2016
Nov 28 / Zacks.com - Paid Partner Content
The Main Reason Achillion Pharmaceuticals, Inc. Collapsed 34% in November
Dec 05 / MotleyFool.com - Paid Partner Content
Company News for November 28, 2016
Nov 28 / Zacks.com - Paid Partner Content
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Nx...
Dec 05 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: Lilly Alzheimer's Drug Fails, J&J in Acquisition Talks with ALI...
Nov 28 / Zacks.com - Paid Partner Content
Stock Futures Rise as Wall Street Shrugs Off Italy Referendum Defeat; Oil Gains
Dec 05 / TheStreet.com - Paid Partner Content
J&J (JNJ) Confirms it Approached Actelion for Possible Deal
Nov 28 / Zacks.com - Paid Partner Content
5 Things You Must Know Before the Market Opens Monday
Dec 05 / TheStreet.com - Paid Partner Content
3 Predictions for Intuitive Surgical in 2017
Nov 27 / MotleyFool.com - Paid Partner Content
Acceleron, Celgene Seek to Replace Entrenched Anti-Anemia Drugs in MDS Treatment
Dec 04 / TheStreet.com - Paid Partner Content
J&J confirms talks with Actelion over pharma deal
Nov 25 / FT.com - Paid Partner Content
US corporate bonds: The weight of debt
Dec 04 / FT.com - Paid Partner Content
Nothing is cheap, says the investment house hoarding cash
Nov 15 / FT.com - Paid Partner Content